Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Epipen Price Rise:...

    Epipen Price Rise: Lawmakers press Mylan

    Written by savita thakur thakur Published On 2016-08-23T15:43:17+05:30  |  Updated On 23 Aug 2016 3:43 PM IST

    The price of a pack of two EpiPens had gone from $100 in 2008 to $500 this year.


    Two senior lawmakers on the U.S. Senate's Judiciary Committee pushed for information regarding sharp price increases for EpiPens, drug-filled injectable devices used by people to counter potentially deadly allergic reactions.


    Senator Chuck Grassley, chairman of the Senate Judiciary Committee, wrote Mylan Chief Executive Heather Bresch to ask how Mylan determined the price of EpiPens and what changes had been made to the product to account for the higher price.


    The top Democrat on the committee's antitrust subcommittee, Senator Amy Klobuchar, urged the Federal Trade Commission to investigate the prices, citing news reports showing that the price of a pack of two EpiPens had gone from $100 in 2008 to $500 this year. Mylan acquired the product in 2007.


    "Although the antitrust laws do not prohibit price gouging, regardless of how unseemly it may be, they do prohibit the use of unreasonable restraints of trade to facilitate or protect a price increase," wrote Klobuchar, a Minnesota Democrat who said her daughter relies on an EpiPen.


    "The FTC should investigate whether Mylan Pharmaceuticals engaged in activity, such as using incentives or exclusionary contracts with insurers, distributors, or pharmacies, to deny an alternative product access to the market."


    An EpiPen injects a pre-measured dose of epinephrine (adrenaline) that people use if they are having a dangerous allergic reaction.


    The FTC did not say whether an investigation was under way. "The commission takes seriously its obligation to take action where pharmaceutical companies have violated the antitrust laws," a spokesman said.


    Mylan did not immediately comment on the letters but noted in an email that nearly 80 percent of people with commercial insurance who use a savings card can get the medicine for free.


    "With changes in the healthcare insurance landscape, an increasing number of people and families are enrolled in high deductible health plans, and deductible amounts continue to rise. This shift has presented new challenges for consumers, and they are bearing more of the cost," Mylan also said.


    The FTC opened a probe into Turing Pharmaceuticals for possible antitrust violations in connection with the company's decision to sharply raise the price of a life-saving drug. Turing had raised the price of Daraprim to $750 a tablet from $13.50.

    Amy KlobucharEpiPenFederal Trade CommissionFTChealthcare insuranceHeather BreschMylanprice increases
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok